Abstract:ABSTRACT:Objective To study the efficacy and safety of oxcarbazepine (OXC)oral suspension on children with different kinds of epilepsy.Methods A total of 83 children with epilepsy were selected from the Pediatric Department of the First Affiliated Hospital of Xi’an Jiaotong University and Xi’an Children’Hospital from June 201 1 to June 2014.They were treated with OXC monotherapy or adjunctive therapy.Use open-label and self-contrast method.The initial dose of OXC was 8 -10 mg/(kg·d),and then was added 10 mg/(kg·d)per 7 days until it reached the minimum effective dose.Generally,the maintenance dose was about 20-40 mg/(kg·d).The follow-up duration was 6 - 12 months.Results 83 cases were eventually included and 5 cases withdrew.We elvaluated the efficacy every 3 months.The results were as follows:the first stage (1,2,3 months)resulted in a 41.0% of full control rate and a 71.8% of total effective rate;the second stage (4,5,6 months)resulted in a 46.2% of full control rate and a 76.9% of total effective rate;the third stage (7,8,9 months)resulted in a 59.0%of full control rate and a 79.5% of total effective rate.There were no significant differences in the efficacy of the three stages.54 cases with partial seizures resulted in a 59.3% of full control rate and a 79.6% of total effective <br> rate;24 cases with generalized seizure resulted in a 45.8% of full control rate and a 62.5% of total effective rate. There was no statistical significant difference in the efficacy of the two seizure types.43 cases with monotherapy resulted in a 58% of full control rate and a 79% of total effective rate,35 cases with add-on therapy resulted in a 40.0% of full control rate and a 57.1% of total effective rate.24 cases with < 2 resulted in a 41.7% of full control rate and a 62.5% of total effective rate,54 cases with 2-6 resulted in a 59.3% of full control rate and a 83.3% of total effective rate.14 cases of children were reported to have at least one adverse drug reactions,the specific symptoms included emotional instability unstable, hypohidrosis, somnolence, dizzness, headache, vomiting, urorrhea,lack of appetite,aggressive behavior and hypomnesia.Adverse reactions were mild and most of them could subside over time.Conclusion OXC oral suspension has a good efficacy and safety when treating children with partial seizures or generalized tonic-clonic seizures of epilepsy.

Serum concentration analysis of oxcarbazepine active metabolite in children with epilepsy

Blood Serum Concentration Monitoring for Oxcarbazepine Metabolites in 217 Children with Epilepsy

Analysis of the Influencing Factors of the Plasma Concentration of Oxcarbazepine Active Metabolite in Children with Epilepsy

Saliva And Plasma Monohydroxycarbamazepine Concentrations In Pediatric Patients With Epilepsy

Relationship Between Cytochromes P450 2C19 * 2 Genotype and the Concentration of the Active Oxcarbazepine Metabolite in Pediatric Patients with Epilepsy

Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children

Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy

An HPLC Method for Simultaneous Determination of Plasma Concentration of Lamotrigine and Oxcarbazepine Active Metabolite and Its Application in Children with Epilepsy

Population Pharmacokinetic Modeling of Oxcarbazepine Active Metabolite in Chinese Patients with Epilepsy.

Population Pharmacokinetics Modeling of Oxcarbazepine to Characterize Drug Interactions in Chinese Children with Epilepsy

Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy

Initial Therapeutic Target Attainment of Perampanel in Pediatric Patients with Epilepsy

Efficacy and safety of oxcarbazepine oral suspension in epileptic children:a clinical study

Affecting Factors of Serum Carbamazepine Concentrations in Children with Epilepsy

Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients

Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI

Oxcarbazepine Oral Suspension in Partial Epilepsy of Preschool-Aged Children: an Efficacy and Safety Study

Determination of Active Metabolite of Oxcarbazepine by RP-HPLC and Study of Its Pharmacokinetics in Chinese Healthy Volunteers

Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric patients with epilepsy: Model‐based dose optimization

Development and Validation of a Highly Sensitive and Rapid LC-MS3 Strategy to Determine Oxcarbazepine and Its Active Metabolite in the Serum of Patients with Epilepsy and Its Application in Therapeutic Drug Monitoring

Clinical Observation of Oxcarbazepine on the Children with Epilepsy